Dermira Inc. (NASDAQ: DERM) shares more than doubled on Monday after the firm announced midstage results from its eczema study. Specifically, Dermira announced positive results from its Phase 2b dose-ranging study of lebrikizumab in adult patients with moderate-to-severe atopic dermatitis.
Overall, each of the three doses of lebrikizumab met the primary endpoint, demonstrating greater improvements in the Eczema Area and Severity Index (EASI) score compared to placebo. The safety profile for lebrikizumab observed in the study was consistent with prior studies.
Some quick background: lebrikizumab is a novel, injectable, humanized monoclonal antibody designed to bind interleukin-13 (IL-13) with high affinity, specifically preventing the formation of the IL-13Rα1/IL-4Rα heterodimer complex, which inhibits downstream signaling. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening and infection.
Emma Guttman-Yassky, M.D., Ph.D., The Sol and Clara Kest Professor, Vice Chair for Research in the Department of Dermatology, director of the Center of Excellence in Eczema at Icahn School of Medicine at Mount Sinai and a leading study investigator, commented:
These data are compelling and further demonstrate clinically that IL-13 is a key mediator in atopic dermatitis. I have many patients for whom current therapies do not adequately address their needs. These data show that lebrikizumab may offer a targeted, effective and well-tolerated therapeutic approach.
Shares of Dermira were last seen up about 105% at $14.00 on Monday, in a 52-week range of $6.00 to $14.85. The consensus price target is $17.22.
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
